Table 5.
Inducers and suppressors of the expression of CYP3A7.
| Chemical | Host | Up/Down regulation of expression | Reference |
|---|---|---|---|
| Dexamethasone | HepG2/fetal hepatocytes | Up | [101,103] |
| Betamethasone | Fetal hepatocytes | Up | [103] |
| Prednisolone | Fetal hepatocytes/HepG2 | Up | [103,104] |
| Methylprednisolone | Fetal hepatocytes | Up | [103] |
| Fludrocortisone | Fetal hepatocytes | Up | [103] |
| Rifampicin | HepG2 | Up | [104] |
| Phenytoin | HepG2 | Up | [104] |
| Clotrimazole | HepG2 | Up | [104] |
| Cyclosporine | HepG2 | Up | [104] |
| Carbamazepine | HepG2 | Up | [104] |
| Phenobarbital | HepG2 | Up | [104] |
| 4-monochloropheno | HepG2 | Up | [105] |
| Beclomethasone dipropionate | DPX2 | Up | [106] |
| Endosulfan | HepG2 | Up | [107] |
| Chemotherapeutic agents (cisplatin, etoposide or doxorubicin) | HepG2 | Up | [108] |
| Pentachlorophenol | HepG2 | Up | [109] |
| U0126 | HepG2 | Up | [110] |
| Maternal smoking | Fetal livers | Up | [111] |
| Apple polyphenols extract | Colon adenoma LT97 cell | Up | [102] |
| Neonicotinoids (thiacloprid, thiamethoxam, imidacloprid) | H295R cells | Up | [112] |
| Pargyline | Human primary fetal liver cells, HepG2 | Up | [113] |
| Chronic cadmium exposure | HepG2 | Up | [114] |
| Rifampicin | HepG2, hepatocytes | Up | [115,116] |
| Troleandomycin | HepG2 | Up | [116] |
| Erythromycin | HepG2 | Up | [116] |
| Phenobarbital | HepG2 | Up | [116] |
| Phenobarbital-like inducers | HepG2 | Up | [116] |
| Lovastatin | HepG2 | Up | [116] |
| 5-aza-2′-deoxycytidine | HepG2 | Up | [117] |
| St. John's wort | HepG2 | Down | [101] |
| Troglitazone | HepG2 | Down | [118] |
| Acute cadmium exposure | HepG2 | Down | [114] |
Up: upregulated; down: downregulated.